N
EBS icon

Nuveen’s Emergent Biosolutions EBS Stock Holding History

Nuveen’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,700
Closed -$1K – 3313
2022
Q1 		$1K Buy
+29,700
New +$1.31M ﹤0.01% 3380
2021
Q4 		– Sell
-47,600
Closed -$2K – 3350
2021
Q3 		$2K Buy
+47,600
New +$2.88M ﹤0.01% 3408
2021
Q2 		– Sell
-45,800
Closed -$4K – 3410
2021
Q1 		$4K Buy
+45,800
New +$4.69M ﹤0.01% 3340

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen's EBS Position: Q1 2026 in Review

Nuveen increased its Emergent Biosolutions (EBS) stake by 0.63% in Q1 2026, buying an estimated $6.93K and bringing the position to 106,047 shares worth $880K. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Nuveen first reported a position in EBS in Q2 2015 and has held it in 40 quarters since. The position peaked at $37.8M in Q1 2021. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Nuveen held 106,047 shares of Emergent Biosolutions worth $880K as of Q1 2026.
  • Nuveen bought 669 Emergent Biosolutions shares in Q1 2026, an estimated $6.93K.
  • Emergent Biosolutions made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2634 holding.
  • Nuveen first reported a position in Emergent Biosolutions in Q2 2015 and has held it in 40 quarters since.
  • Nuveen's Emergent Biosolutions position peaked at $37.8M in Q1 2021.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.